PRSS3 and prostate carcinoma: To further explore the therapeutic potential of APPI‐3M, we used an orthotopic mouse model of the highly metastatic PC3‐M human prostate cancer, whose invasiveness has previously been shown to be mesotrypsin dependent [9].